OverviewSuggest Edit

NanoString Technologies is a provider of life science tools for translational research and molecular diagnostics. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system; nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. It also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and pan cancer and 360 gene expression, CAR-T characterization, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, miRNA expression, human organ transplant, human and mouse metabolic pathway, and human and mouse fibrosis panels.
TypePublic
Founded2003
HQSeattle, WA, US
Websitenanostring.com
Employee Ratings3.7
Overall CultureD-

Latest Updates

Employees (est.) (Dec 2019)551(+16%)
Revenue (FY, 2020)$117.3 M(-6%)
Share Price (Mar 2021)$74.4 (+7%)
Cybersecurity ratingCMore

Key People/Management at NanoString Technologies

Brad Gray

Brad Gray

President and Chief Executive Officer
J. Chad Brown

J. Chad Brown

Senior Vice President, Sales and Marketing
Kathy Surace-Smith

Kathy Surace-Smith

Vice President, General Counsel and Corporate Secretary
Thomas Bailey

Thomas Bailey

Chief Financial Officer
Joseph M. Beechem

Joseph M. Beechem

Chief Science Officer & Senior Vice President, Research & Development
David W. Ghesquiere

David W. Ghesquiere

Senior Vice President, Corporate and Business Development
Show more

NanoString Technologies Office Locations

NanoString Technologies has an office in Seattle
Seattle, WA, US (HQ)
530 Fairview Ave N #2000
Show all (1)

NanoString Technologies Financials and Metrics

NanoString Technologies Revenue

Embed Graph
View revenue for all periods
NanoString Technologies's revenue was reported to be $117.32 m in FY, 2020
USD

Revenue (FY, 2020)

117.3m

Gross profit (FY, 2020)

64.9m

Gross profit margin (FY, 2020), %

55.3%

Net income (FY, 2020)

(110.1m)

EBIT (FY, 2020)

(88.0m)

Market capitalization (1-Mar-2021)

3.3b

Closing stock price (1-Mar-2021)

74.4

Cash (31-Dec-2020)

411.8m

EV

3.1b
NanoString Technologies's current market capitalization is $3.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

114.9m106.7m125.6m117.3m

Revenue growth, %

(7%)18%

Cost of goods sold

31.9m36.3m44.0m52.4m

Gross profit

83.0m70.4m81.5m64.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

18.1m34.6m27.0m23.1m25.0m28.6m27.7m30.3m30.6m26.6m21.1m

Cost of goods sold

7.2m8.2m7.3m7.7m8.6m9.3m8.7m9.6m10.9m11.0m

Gross profit

10.9m26.4m19.7m15.4m16.4m19.3m19.0m20.7m19.7m15.6m

Gross profit Margin, %

60%76%73%67%66%68%69%68%64%59%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

26.1m24.4m29.0m411.8m

Accounts Receivable

19.6m17.3m27.2m31.1m

Prepaid Expenses

4.7m7.3m8.8m4.2m

Inventories

20.1m13.2m19.8m23.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.4m40.6m28.8m15.6m24.3m21.2m84.1m33.4m23.4m155.6m168.4m

Accounts Receivable

16.7m18.5m18.3m16.3m17.4m18.5m18.1m19.0m19.5m21.2m22.0m

Prepaid Expenses

4.0m5.3m6.1m5.8m5.9m7.1m8.6m9.2m10.9m5.4m3.2m

Inventories

14.5m15.8m18.5m19.1m17.6m15.0m13.0m16.5m19.0m22.2m26.0m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(43.6m)(77.4m)(40.7m)(110.1m)

Depreciation and Amortization

3.4m4.1m4.9m5.7m

Inventories

(8.7m)5.3m(8.5m)(4.9m)

Accounts Payable

(110.0k)4.6m(599.0k)(3.2m)
USDQ1, 2017

Debt/Equity

-15.6 x

Debt/Assets

0.4 x

Financial Leverage

-34.8 x
Show all financial metrics

NanoString Technologies Operating Metrics

FY, 2017FY, 2018FY, 2019

Product Platforms

1 1 2

Facilities Leased

5 7 8

Patent Applications (US)

40 36 27

Patents and Patent Applications

255 266 290
Show all operating metrics

NanoString Technologies Acquisitions / Subsidiaries

Company NameDateDeal Size
NanoString Technologies Asia Pacific Limited
NanoString Technologies (Bejing) Co. Ltd.
NanoString Technologies Europe Limited
NanoString Technologies Germany GmbH
NanoString Technologies International
NanoString Technologies SAS
NanoString Technologies Singapore Pte Limited
NanoString Technologies Spain, S.L.

NanoString Technologies Revenue Breakdown

Embed Graph

NanoString Technologies revenue breakdown by business segment: 24.7% from Instruments, 41.1% from Consumables, 7.5% from In Vitro Diagnostic Kits, 9.3% from Service and 17.4% from Collaboration

NanoString Technologies revenue breakdown by geographic segment: 68.6% from Americas, 24.1% from Europe & Middle East and 7.3% from Asia Pacific

NanoString Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

NanoString Technologies Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

NanoString Technologies Online and Social Media Presence

Embed Graph

NanoString Technologies Company Culture

  • Overall Culture

    D-

    53/100

  • CEO Rating

    C-

    66/100

  • Compensation

    C-

    63/100

Learn more on Comparably

NanoString Technologies News and Updates

Worldwide Industry for Spatial Genomics and Transcriptomics to 2030 - Players Include NanoString Technologies, S2 Genomics & Flagship Biosciences Among Others

Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "Global Spatial Genomics and Transcriptomics Market: Focus on Product Type, Sample Type, Workflow, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

NanoString Technologies Announces Commencement of Public Offering of Common Stock

SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an underwritten public offering of 4,500,000 shares of its common stock pursuant to its shelf regi…

NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2018

— FY18 Product and Service Revenue of $83.5 million, Exceeding High-End of Guidance —— Generated Pre-Orders for More Than 30 GeoMx™ Digital Spatial Profilers —

NanoString Technologies Blogs

A “Tail” of Two Species: New Canine Immuno-Oncology Research Offering.

NanoString has an unparalleled and longstanding tradition of developing best in class cancer research tools, thanks to an extensive knowledge... The post A “Tail” of Two Species: New Canine Immuno-Oncology Research Offering. appeared first on Nanostring.

Of Mice and Men: The importance of Mouse Models in Research.

Many animals share common biology with humans, are affected by similar diseases, and may have a comparable response to certain... The post Of Mice and Men: The importance of Mouse Models in Research. appeared first on Nanostring.

The Coronavirus Vaccine Ushers in Hope for 2021

Vaccines: biological agents eliciting an immune response to a specific antigen derived from an infectious disease-causing pathogen. The concept of a “vaccine” emerged in 1796, when Edward Jenner developed the first by subcutaneously inoculating smallpox virus into non-immune individuals. Vaccines [……

NanoString Proudly Introduces the new Furry, Slobbery, Four-Legged-Inspired Gene Expression Panel, a.k.a. the nCounter® Canine IO Panel.

It may have happened to you, as it happened to some of us here at NanoString®: the furry, four-legged trouble-making family member you just can’t stay mad at is sick, and the vet doesn’t know what is happening. Tests for […] The post NanoString Proudly Introduces the new Furry, Slobbery, Four-Legged…

AMP-ed Up for Clinical Evaluation with GeoMx DSP

The Association for Molecular Pathology (AMP) joined the list of conferences to go virtual in 2020. NanoString was online with workshops highlighting uses for the groundbreaking GeoMx® Digital Spatial Profiler (DSP) for pathologists and their studies. The seminar “NanoString GeoMx® […] The post AMP-…

SITC in Focus: CAR-T Cell Therapy

The Society for Immunotherapy of Cancer (SITC) held its annual meeting online this year. Notable were the presentations in New Approaches for CAR-T Cell Therapies: Technology Symposium Featuring GeoMx® Digital Spatial Profiler (DSP) and nCounter CAR-T Characterization Panel. Two speakers […] The pos…
Show more

NanoString Technologies Frequently Asked Questions

  • When was NanoString Technologies founded?

    NanoString Technologies was founded in 2003.

  • Who are NanoString Technologies key executives?

    NanoString Technologies's key executives are Brad Gray, J. Chad Brown and Kathy Surace-Smith.

  • How many employees does NanoString Technologies have?

    NanoString Technologies has 551 employees.

  • What is NanoString Technologies revenue?

    Latest NanoString Technologies annual revenue is $117.3 m.

  • What is NanoString Technologies revenue per employee?

    Latest NanoString Technologies revenue per employee is $212.9 k.

  • Who are NanoString Technologies competitors?

    Competitors of NanoString Technologies include EKF Diagnostics, Klox Technologies and Viapath.

  • Where is NanoString Technologies headquarters?

    NanoString Technologies headquarters is located at 530 Fairview Ave N #2000, Seattle.

  • Where are NanoString Technologies offices?

    NanoString Technologies has an office in Seattle.

  • How many offices does NanoString Technologies have?

    NanoString Technologies has 1 office.